Literature DB >> 2360589

The prevalence of substance abuse in patients with suspected preterm labor.

J A Ney1, S L Dooley, L G Keith, I J Chasnoff, M L Socol.   

Abstract

Premature labor is a recognized complication of substance abuse in pregnancy. However, the prevalence of substance abuse in patients first seen with symptoms of preterm labor and who deny use of illicit drugs is unknown. Between July 1, 1988, and December 15, 1988, 141 patients first seen at Northwestern Memorial Hospital in suspected preterm labor and a comparison group of 108 uncomplicated laboring term patients had urine toxicology screening performed to detect substance abuse. Positive urine toxicology screenings were found in 24 of 141 (17.0%) patients with suspected preterm labor and in 3 of 108 (2.8%) patients in the comparison group. The most common substance identified was cocaine (14/24 and 1/3, respectively). Of those patients in suspected preterm labor, 22 of 86 (25.6%) clinic patients had positive urine toxicology screenings as did 2 of 55 (3.6%) private patients. On the basis of our observations, we recommend that patients admitted in possible preterm labor be encouraged to submit to screening for substance abuse so that appropriate counseling and prenatal and neonatal care become available for these high-risk patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2360589     DOI: 10.1016/0002-9378(90)90921-s

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  2 in total

1.  A cohort study of the impact of perinatal drug use on prematurity in an inner-city population.

Authors:  J G Feldman; H L Minkoff; S McCalla; M Salwen
Journal:  Am J Public Health       Date:  1992-05       Impact factor: 9.308

2.  Prevalence of illicit drugs detected in the urine of women of childbearing age in Alabama public health clinics.

Authors:  D A Pegues; M M Engelgau; C H Woernle
Journal:  Public Health Rep       Date:  1994 Jul-Aug       Impact factor: 2.792

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.